M. Christopher Doyle

Whittier Trust Co. is an independent private trust firm headquartered in Pasadena, California. The firm was founded as a family office for the Whittier family in 1935. They provide unrivaled investment, wealth management, fiduciary and philanthropic services for high net-worth families, individuals and foundations across the US.

Delpor, Inc. develops therapeutic products. Its products include DLP-114, DLP-119, DLP-202 and DLP-414. The company was founded by Tassos Nicolaou and Frank Martin in 2009 and is headquartered in San Francisco, CA.

1200 Pharma LLC engages in the provision of pre-clinical drug discovery and clinical approval timelines. The company is headquartered in Pasadena, CA.

Montres Corum SA is a French company that manufactures watches.

Kazakh Steel Plc operates as a holding company. It engages in iron ore exploration. The company was founded on September 28, 2021 and is headquartered in Aktobe City, Kazakhstan.

Satco, Inc. manufactures air cargo container and pallets. The company was founded by Robert Looker in 1968 and is headquartered in El Segundo, CA.

Primexx Energy Partners Ltd. acquires, develops, and produces domestic onshore oil and gas reserves. The company was founded in 2001 and is headquartered in Dallas, TX.

Part of BrightSphere Investment Group, Inc., TSA Capital Management is a quantitative investment management company. The company is based in Los Angeles, CA. TSA Capital Management was acquired by Analytic Investment Management, Inc. on February 05, 1996.

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

Northern Trust of California, NA (NTC) is an investment management firm headquartered in Los Angeles, California. They are a subsidiary of Northern Trust Corp. (NASDAQ: NTRS). NTC provides investment solutions to individuals, families, and institutions.

TORL Biotherapeutics LLC is a clinical-stage biopharmaceutical company based in Culver City, CA. TORL Biotherapeutics LLC is focused on developing new antibodies, including monoclonal antibodies (mAbs) and drug conjugates (ADCs), to transform the lives of patients with various types of cancer. TORL has a strategic partnership with the Slamon Research Lab and has exclusive rights to a program of biologics-based drugs for novel cancer targets. The company's lead program, TORL-1-23, is an ADC directed towards cldn6 for patients with multiple cancers. In addition to this, TORL has four other clinical-stage antibody programs and is building a pipeline of novel ADCs and mAbs for cancers with high unmet medical needs. The company was founded by David Licata, and the CEO is Mark J. Alles.